Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

QLGN
Qualigen Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open
May 29, 2025 10:36:13 AM EDT
3.78USD-0.526%(-0.02)950
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 27, 2025 9:21:30 AM EDT
3.73USD-1.842%(-0.07)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 18, 2022
09:19AM EST  Qualigen Therapeutics Reports Secured Global Rights To G4-Selective Transcription Inhibitors From University College London To Develop As Cancer Therapeutics, No Terms Disclosed   Benzinga
09:15AM EST  Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer   GlobeNewswire Inc
Dec 14, 2021
09:18AM EST  Qualigen Therapeutics Promotes Amy Broidrick to President   GlobeNewswire Inc
Dec 1, 2021
03:25PM EST  Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announcedthe closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).   GlobeNewswire Inc
Nov 30, 2021
04:27PM EST  Qualigen Therapeutics Announces $8.82M Offering   Benzinga
Nov 29, 2021
03:50PM EST  QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK   GlobeNewswire Inc
Nov 27, 2021
11:01AM EST  QLGN: Revenues Increase 38% YoY   Benzinga
Nov 24, 2021
10:23AM EST  Mid-Morning Market Update: Markets Open Lower; Deere Earnings Top Views   Benzinga
Nov 23, 2021
09:53AM EST  Qualigen Therapeutics, Inc. (QLGN) shares are surging more than 47 percent on Tuesday morning trade, continuing an upsurge since November 18. There were no corporate announcements on the day to impact the stock movement.   RTTNews
Nov 15, 2021
11:17AM EST  Qualigen Therapeutics Q3 EPS $(0.10) Down From $0.41 YoY, Sales $1.16M Up From $1.11M YoY   Benzinga
09:00AM EST  -- Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous year -- Year-to-date revenues increased 30%to $4.2 million, compared to $3.2million in the same nine-month period of the previous year -- Cash equivalents of approximately $12.3 million as of September 30, 2021   GlobeNewswire Inc
Oct 19, 2021
09:08AM EDT  Qualigen Highlights Publication Of Study In Diagnostics On Co.'s FastPack   Benzinga
09:00AM EDT  Peer-Reviewed Article Confirms That Qualigens   GlobeNewswire Inc
Sep 15, 2021
07:30AM EDT  Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 20-23, 2021.   GlobeNewswire Inc
Sep 8, 2021
07:30AM EDT  Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today that CEO and Chairman Michael Poirier will present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021.   GlobeNewswire Inc
Sep 5, 2021
07:01AM EDT  QLGN: Focusing on Advancement of QN-247 and RAS-F   Benzinga
Aug 23, 2021
09:58AM EDT  4 Penny Stocks Insiders Are Buying   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:26AM EDT  Qualigen Therapeutics Q2 EPS $(0.18) Up From $(0.41) YoY, Sales $1.10M Up From $837.71K YoY   Benzinga
08:00AM EDT  Qualigen Therapeutics, Inc. Provides Update on Product Development   GlobeNewswire Inc
05:52AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 5.37 A.M. EDT).   RTTNews
Jul 14, 2021
08:27AM EDT  Qualigen Files US Application To Start Human Trials For COVID-19 Candidate   Benzinga
07:31AM EDT  Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug Application for QN-165, for the Treatment of COVID-19   Benzinga
Jul 7, 2021
02:41PM EDT  QLGN: On Track to File IND for QN-165 as COVID-19 Treatment in   Benzinga
Jun 8, 2021
07:30AM EDT  Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that according to a preliminary list of additions posted June 4 it will be added to the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, 2021.   GlobeNewswire Inc
Jun 2, 2021
07:30AM EDT  Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that its CEO and Chairman Michael Poirier will present and participate at the virtual LD Micro Invitational XI Conference, hosted by Sequire Virtual Events, taking place on June 8-10, 2021.   GlobeNewswire Inc
May 19, 2021
03:39PM EDT  Qualigen Shares Move Higher On Volume Following Circulation Of A European Patent Office Filing For Co.'s 'SYSTEMS AND METHODS FOR SAMPLE VERIFICATION'   Benzinga
07:30AM EDT  New Position Created toDeepen Clinical Expertise and Advance Pipeline Therapeutic Programs   GlobeNewswire Inc
May 14, 2021
01:37PM EDT  Qualigen Therapeutics Q4 EPS $(0.13), Sales $1.90M   Benzinga
01:35PM EDT  Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial   GlobeNewswire Inc
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
Apr 28, 2021
05:41PM EDT  QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2H21   Benzinga
Apr 19, 2021
01:16PM EDT  Qualigen Therapeutics Plans to Combat COVID-19 Variants   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 12, 2021
07:43AM EDT  Why Is Qualigen Stock Trading Lower Today?   Benzinga
07:40AM EDT  Why Qualigen Stock Is Trading Lower Today?   Benzinga
Mar 31, 2021
02:52PM EDT  Qualigen Therapeutics Receives Intention To Grant A Patent From European Patent Office Doc Titled 'SYSTEMS AND METHODS FOR SAMPLE VERIFICATION'   Benzinga
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 24, 2021
09:02AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Mar. 24, 2021: PRPH, QLGN, SRNE, GLSI, AMPE   Benzinga
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
Mar 18, 2021
08:30AM EDT  Qualigen Therapeutics, Inc. to present at the Benzinga Biotech   GlobeNewswire Inc
Mar 9, 2021
09:17AM EST  Qualigen Therapeutics Names Shishir Sinha To COO   Benzinga
08:30AM EST  Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announced today that it has promoted long-time officer Shishir Sinha to the newly created position of Chief Operating Officer. Mr. Sinha is based in Qualigens corporate headquarters in Carlsbad, California.   GlobeNewswire Inc
Mar 8, 2021
08:47AM EST  Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen, will present at the Oppenheimer 31st Annual Healthcare Conference being held March 16-18 2021.   GlobeNewswire Inc
Mar 1, 2021
08:30AM EST  Qualigen Therapeutics Secures Option to Negotiate License for   GlobeNewswire Inc
Jan 26, 2021
09:21AM EST  Qualigen Completes Milestone Related To License And Tech Transfer Of FastPack Diagnostics Products In China   RTTNews
09:04AM EST  Qualigen Therapeutics Announces Completion of Milestone Related to the License   PR Newswire
09:02AM EST  Qualigen Therapeutics Announces Completion Of Milestone Related To License and Technology Transfer Of Its FastPack Diagnostics Products In China, Triggering Payment Obligation From Yi Xin Zhen Duan Jishu   Benzinga
Jan 5, 2021
09:02AM EST  Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021   PR Newswire
Dec 30, 2020
11:17AM EST  Insider Buys Qualigen Therapeutics Stock   Benzinga
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 22, 2020
09:03AM EST  Qualigen Therapeutics Issues CEO Letter To Stockholders; Sees ~$24M In Cash Going Into 2021   Benzinga
09:01AM EST  Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook   PR Newswire
Dec 18, 2020
03:08PM EST  Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct   PR Newswire
Dec 16, 2020
10:26AM EST  Qualigen Prices 3.27M Share, Warrant Offering At Combined Price Of $3.56/Unit   Benzinga
10:25AM EST  Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering   PR Newswire
Dec 15, 2020
09:06AM EST  Qualigen Therapeutics Announces Issuance Of US Patent For Expanded Applications Of ALAN Anticancer Platform Technology   Benzinga
09:03AM EST  Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded   PR Newswire
Dec 8, 2020
09:38AM EST  IQualigen Therapeutics Appoints Amy Broidrick As EVP, Chief Strategy Officer   RTTNews
09:03AM EST  Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief   PR Newswire
Dec 2, 2020
09:03AM EST  Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply   PR Newswire
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
Nov 13, 2020
09:10AM EST  Qualigen Therapeutics Yesterday Reported Q2 EPS $(0.41), Sales $837.71K   Benzinga
09:07AM EST  Qualigen Therapeutics Q2 Total Revenues $0.8 Mln Vs. $1.2 Mln Prior Year   RTTNews
09:03AM EST  Qualigen Therapeutics Issues CEO Letter To Stockholders   Benzinga
09:01AM EST  Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant   PR Newswire
08:17AM EST  Stocks Trading Near 52-Week Lows Before Open On Friday, Nov. 13, 2020: FIIIU, SFT, QLGN,   Benzinga
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 5, 2020
09:08AM EST  Qualigen Therapeutics Engages STA Pharmaceutical As GMP Manufacturer Of AS1411 For Clinical Trials   Benzinga
09:01AM EST  Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411   PR Newswire
Oct 28, 2020
09:03AM EDT  Qualigen Receives Positive Pre-IND Response From FDA For Clinical Development Of AS1411 As Treatment For COVID-19   RTTNews
09:02AM EDT  Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the   PR Newswire
09:01AM EDT  Qualigen Therapeutics Receives Pre-IND Response From FDA For Clinical Development Of AS1411 As A Treatment for COVID-19; FDA In General Agreement With Co.'s Planned Development, IND Application And Phase 2a Study Planned For 1H 2021   Benzinga
Oct 8, 2020
09:05AM EDT  Qualigen Enters Into Commercialization Deal For Its FastPack Diagnostic Products In China   RTTNews
09:01AM EDT  Qualigen Therapeutics Reports Commercialization Deal For FastPack Diagnostic Products In China, No Terms Disclosed   Benzinga
09:01AM EDT  Qualigen Therapeutics Enters into Commercialization Agreement for its   PR Newswire
Oct 1, 2020
09:23AM EDT  Qualigen Therapeutics Reports Expansion Of Research Deal With University Of Louisville For ALAN Cancer Drug Candidate   Benzinga
09:02AM EDT  Qualigen Therapeutics Expands Research Agreement with University of Louisville   PR Newswire
Sep 27, 2020
02:03AM EDT  QLGN: Initiating Coverage of Qualigen Therapeutics, Inc.; Targeting Cancer and Infectious Diseases   Benzinga
Sep 17, 2020
09:02AM EDT  Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application   PR Newswire
Aug 31, 2020
09:04AM EDT  Qualigen Therapeutics Reports Engaged IRISYS As GMP Manufacturer For AS1411 Drug Product   Benzinga
09:01AM EDT  Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug   PR Newswire
Aug 25, 2020
12:27PM EDT  Qualigen Therapeutics Shares Spike Higher; Hearing Earlier Alliance Global Partners Raised From Neutral To Buy; Co Also Announced Issuance Of STARS Technology Patent   Benzinga
Aug 20, 2020
09:53AM EDT  Qualigen Therapeutics shares are trading higher after the company announced that it received issuance of its STARS Technology patent by the US patent and trademark office.   Benzinga
08:05AM EDT  Qualigen Announces Issuance Of STARS Technology Patent By U.S. Patent And Trademark Office   RTTNews
08:03AM EDT  Qualigen Therapeutics Announces Issuance Of STARS Technology Patent By The US Patent And Trademark Office   Benzinga
08:01AM EDT  Qualigen Therapeutics Announces Issuance of STARS(tm) Technology Patent by the   PR Newswire
Aug 18, 2020
02:04PM EDT  Qualagin Granted U.S. Patent Titled 'Devices and methods for on-line whole blood treatment'   Benzinga
Aug 14, 2020
05:25PM EDT  Qualigen Therapeutics Announces Business Highlights and First Quarter Fiscal   PR Newswire
Aug 6, 2020
04:00PM EDT  Qualigen Therapeutics to Host Business Update Conference Call on August 18, 2020   PR Newswire
Aug 4, 2020
04:06PM EDT  Qualigen Therapeutics, Inc. Announces Closing of $10 Million Registered Direct   PR Newswire
Aug 2, 2020
05:51PM EDT  Qualigen Therapeutics Prices $10M Registered Direct Offering Involving a Single Institutional Investor @$5.73/Common Share and $0.125/Common Warrant   Benzinga
05:33PM EDT  Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering   PR Newswire
Jul 30, 2020
08:42AM EDT  Qualigen Therapeutics Begins Shipping FastPack Coronavirus Antibody Test   Benzinga
08:07AM EDT  Qualigen Therapeutics Says Begins Shipping FastPack COVID-19 Antibody Test   RTTNews
08:01AM EDT  Qualigen Therapeutics Begins Shipping FastPack(r) COVID-19 Antibody Test   PR Newswire
Jul 22, 2020
08:07AM EDT  Qualigen Therapeutics Signs Exclusive License Agreement With University Of Louisville For RAS Interaction Inhibitor Drug Candidates   Benzinga
08:03AM EDT  Qualigen Signs License Agreement With University Of Louisville For RAS Interaction Inhibitor Drug Candidates   RTTNews
08:01AM EDT  Qualigen Therapeutics Signs Exclusive License Agreement with the University of   PR Newswire
Jul 13, 2020
08:12AM EDT  Qualigen Plans To Advance Trials With Pipeline Of Drug Candidates For Treatment Of Certain Cancers &infectious Diseases   RTTNews
08:01AM EDT  Qualigen Therapeutics CEO Issues Letter to Stockholders   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC